The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally transformed the landscape of metabolic medicine, offering unprecedented efficacy…
Read More

The rapid rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally transformed the landscape of metabolic medicine, offering unprecedented efficacy…
Read More
A research team co-led by a physician-scientist at the University of Arizona College of Medicine – Tucson’s Sarver Heart Center…
Read More
The human brain has long been perceived as a highly shielded organ, protected by the blood-brain barrier and floating in…
Read More
The pharmaceutical landscape of the 21st century has been fundamentally altered by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists.…
Read More
A multi-institutional research initiative, co-led by a physician-scientist at the University of Arizona College of Medicine – Tucson’s Sarver Heart…
Read More
The pharmaceutical landscape of the 2020s has been defined by the meteoric rise of GLP-1 receptor agonists. Drugs such as…
Read More
The United States Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) from…
Read More
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally altered the landscape of metabolic medicine in the United States.…
Read More
In a landmark study that challenges long-held medical dogmas regarding the permanent nature of cardiac damage, a multidisciplinary research team…
Read More
As the prevalence of glucagon-like peptide-1 (GLP-1) receptor agonists continues to reshape the landscape of metabolic health in the United…
Read More